NRx Pharmaceuticals Inc. (NRXP)
NRx Pharmaceuticals Inc. (NRXP) Stock Price, Analysis & Data
| Bid | 2.61 |
| Market Cap | 145.52M |
| Revenue (ttm) | 2.29M |
| Net Income (ttm) | -24.54M |
| Beta | 2.18 |
| EPS (ttm) | -1.04 |
| PE Ratio (ttm) | n/a |
| Forward PE | 6.8 |
| P/B (ttm) | -8.23 |
| P/S (ttm) | 63.46 |
| Earnings Date | Aug 14, 2026 |
| Ask | 4.28 |
| Volume | 251,253 |
| Avg. Volume (20D) | 1,287,483 |
| Open | 3.40 |
| Previous Close | 3.40 |
| Day's Range | 3.38 - 3.50 |
| 52-Week Range | 1.62 - 5.05 |
| Analyst | Strong Buy |
| Price Target | 49 (1341.18%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NRXP
NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depressi...
Financial Performance
In 2025, NRx Pharmaceuticals's revenue was 1.23M, an increase of undefined% compared to the previous year's 0. Earnings were -28.62M, an increase of 13.91%.
Financial StatementsAnalyst Forecast
According to 3 analyst ratings, the average rating for NRXP stock is "Strong Buy". The 12-month stock price forecast is 49, which is upside of 1341.18% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
